JP Morgan Chase’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.08B Buy
22,783,175
+1,038,463
+5% +$87M 0.12% 169
2026
Q1
$1.73B Sell
21,744,712
-4,280,140
-16% -$353M 0.11% 182
2025
Q4
$2.22B Buy
26,024,852
+966,326
+4% +$79.3M 0.14% 156
2025
Q3
$1.95B Sell
25,058,526
-1,714,961
-6% -$134M 0.12% 172
2025
Q2
$2.09B Buy
26,773,487
+4,811,521
+22% +$359M 0.14% 149
2025
Q1
$1.59B Buy
21,961,966
+7,110,139
+48% +$509M 0.12% 178
2024
Q4
$1.1B Buy
14,851,827
+6,385,779
+75% +$447M 0.08% 229
2024
Q3
$559M Sell
8,466,048
-212,869
-2% -$15.5M 0.04% 361
2024
Q2
$802M Sell
8,678,917
-922,139
-10% -$81.7M 0.07% 266
2024
Q1
$917M Buy
9,601,056
+1,770,391
+23% +$149M 0.08% 247
2023
Q4
$597M Buy
7,830,665
+4,332,955
+124% +$301M 0.06% 314
2023
Q3
$242M Buy
3,497,710
+317,229
+10% +$25.5M 0.03% 501
2023
Q2
$300M Buy
3,180,481
+767,847
+32% +$66.7M 0.03% 448
2023
Q1
$200M Buy
2,412,634
+587,461
+32% +$46.2M 0.02% 546
2022
Q4
$136M Sell
1,825,173
-196,581
-10% -$15.2M 0.02% 653
2022
Q3
$167M Buy
2,021,754
+50,418
+3% +$4.85M 0.02% 541
2022
Q2
$187M Buy
1,971,336
+671,264
+52% +$69.5M 0.03% 528
2022
Q1
$153M Buy
1,300,072
+199,094
+18% +$22.3M 0.02% 662
2021
Q4
$143M Sell
1,100,978
-10,693
-1% -$1.25M 0.02% 710
2021
Q3
$126M Sell
1,111,671
-41,284
-4% -$4.71M 0.02% 761
2021
Q2
$119M Sell
1,152,955
-664,028
-37% -$62.6M 0.01% 815
2021
Q1
$152M Buy
1,816,983
+60,439
+3% +$5.11M 0.02% 666
2020
Q4
$160M Buy
1,756,544
+38,508
+2% +$3.19M 0.02% 605
2020
Q3
$135M Buy
1,718,036
+298,153
+21% +$23.3M 0.02% 593
2020
Q2
$98.1M Sell
1,419,883
-1,013,537
-42% -$72M 0.02% 660
2020
Q1
$153M Buy
2,433,420
+1,371,828
+129% +$98.9M 0.04% 450
2019
Q4
$82.6M Buy
1,061,592
+76,857
+8% +$6M 0.02% 745
2019
Q3
$72.2M Sell
984,735
-243,603
-20% -$17.1M 0.01% 785
2019
Q2
$75.9M Sell
1,228,338
-1,017,993
-45% -$61.6M 0.01% 777
2019
Q1
$143M Buy
2,246,331
+23,025
+1% +$1.31M 0.03% 533
2018
Q4
$114M Buy
2,223,306
+17,025
+0.8% +$861K 0.03% 581
2018
Q3
$128M Sell
2,206,281
-158,907
-7% -$7.77M 0.02% 593
2018
Q2
$115M Buy
2,365,188
+649,779
+38% +$30.3M 0.02% 604
2018
Q1
$79.8M Sell
1,715,409
-195,768
-10% -$8.5M 0.02% 725
2017
Q4
$71.8M Buy
1,911,177
+217,986
+13% +$8M 0.02% 801
2017
Q3
$61.4M Buy
1,693,191
+100,041
+6% +$3.82M 0.01% 817
2017
Q2
$62.8M Sell
1,593,150
-24,363
-2% -$889K 0.01% 809
2017
Q1
$50.7M Sell
1,617,513
-397,518
-20% -$12.4M 0.01% 943
2016
Q4
$62.9M Sell
2,015,031
-688,455
-25% -$22.3M 0.02% 776
2016
Q3
$109M Sell
2,703,486
-555,282
-17% -$20.9M 0.03% 532
2016
Q2
$108M Buy
3,258,768
+238,431
+8% +$8.16M 0.03% 538
2016
Q1
$88.8M Buy
3,020,337
+412,374
+16% +$11.4M 0.02% 575
2015
Q4
$68.7M Buy
2,607,963
+90,897
+4% +$2.36M 0.02% 682
2015
Q3
$59.6M Sell
2,517,066
-17,856
-0.7% -$431K 0.02% 714
2015
Q2
$60.2M Buy
2,534,922
+428,052
+20% +$9.66M 0.01% 804
2015
Q1
$50M Sell
2,106,870
-615,546
-23% -$13.8M 0.01% 898
2014
Q4
$57.8M Sell
2,722,416
-1,224,084
-31% -$24.6M 0.01% 868
2014
Q3
$67.2M Buy
3,946,500
+3,195,300
+425% +$50.4M 0.02% 777
2014
Q2
$10.7M Sell
751,200
-1,758,990
-70% -$23.8M ﹤0.01% 1702
2014
Q1
$31M Buy
2,510,190
+955,068
+61% +$11M 0.01% 1075
2013
Q4
$17M Sell
1,555,122
-465,192
-23% -$5.24M ﹤0.01% 1430
2013
Q3
$23.4M Sell
2,020,314
-11,868
-0.6% -$139K 0.01% 1235
2013
Q2
$22.8M Buy
+2,032,182
New +$24.1M 0.01% 1177

Other funds holding EW

JP Morgan Chase's EW Position: Q2 2026 in Review

JP Morgan Chase increased its Edwards Lifesciences (EW) stake by 4.8% in Q2 2026, buying an estimated $87M and bringing the position to 22,783,175 shares worth $2.08B. The position accounts for 0.12% of the portfolio, ranked #169.

JP Morgan Chase first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.22B in Q4 2025. 1,328 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • JP Morgan Chase held 22,783,175 shares of Edwards Lifesciences worth $2.08B as of Q2 2026.
  • JP Morgan Chase bought 1,038,463 Edwards Lifesciences shares in Q2 2026, an estimated $87M.
  • Edwards Lifesciences made up 0.12% of JP Morgan Chase's portfolio in Q2 2026, its #169 holding.
  • JP Morgan Chase first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Edwards Lifesciences position peaked at $2.22B in Q4 2025.
  • 1,328 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.